Vyome Holdings, Inc. — 2022 Q2 filing summary
Filing identity: The supplied filing is a Form 10-Q for ReShape Lifesciences Inc., not Vyome Holdings, Inc. It covers the quarter and six months ended June 30, 2022; amounts below are in U.S. dollars unless noted.
Business context and reporting period
ReShape markets obesity-related products and services, principally the Lap-Band system. Its portfolio also includes ReShapeCare and the ReShape Marketplace; the ReShape Vest and Diabetes Bloc-Stim Neuromodulation remain in development. The company reported no revenue from the acquired Obalon line. Its markets include the United States, Australia, Europe and other regions.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | $2.892 million | $5.332 million |
| Gross profit / margin | $1.883 million / 65.1% | $3.101 million / 58.2% |
| Operating loss | $9.376 million | $17.775 million |
| Net loss | $9.576 million | $17.791 million |
| Net loss per share, basic and diluted | $0.50 | $0.94 |
| Operating cash used | $13.800 million for the six-month period |
Compared with June 30, 2021, Q2 revenue fell 18.1% and six-month revenue fell 21.0%. Q2 gross margin improved from 61.0% to 65.1%, but the six-month margin declined from 65.7% to 58.2%. The six-month net loss more than doubled year over year.
At June 30, cash and cash equivalents were $11.494 million, plus $0.050 million of restricted cash; accounts receivable was $2.448 million. Net working capital was approximately $10.3 million. Total liabilities were $9.562 million and stockholders’ equity was $32.363 million. The balance sheet shows no outstanding credit-agreement borrowing; operating lease liabilities were $0.338 million, current. Cash declined by $11.271 million during the first half.
Material changes and unusual items
- Sales and marketing expense rose to $4.663 million in Q2 and $9.371 million for the first half, primarily reflecting expansion of direct-to-consumer marketing, hiring and related commercial costs.
- General and administrative expense included a $2.0 million litigation accrual. The company also reported a $0.381 million loss on disposal of assets acquired with Obalon.
- In June, a warrant exercise generated approximately $2.5 million gross proceeds. The agreement also issued new warrants and reduced the exercise price of certain existing warrants, creating potential dilution. Common shares outstanding were 19,629,708 at June 30 and 22,559,404 at August 15, 2022.
- The company revised previously reported weighted-average share counts and loss-per-share figures to correct an immaterial calculation error. The revision did not affect net loss or accumulated deficit.
Outlook, risks and contingencies
Management attributed weaker sales partly to COVID-19-related bariatric-center closures during December 2021 through February 2022. It said revenue had begun to recover and expected it to continue increasing through the rest of 2022, citing web traffic and physician consultations following direct-to-consumer marketing. This was not quantified guidance.
The company warned that available cash might not fund operations for more than twelve months from the filing date, raising substantial doubt about its ability to continue as a going concern. Management was evaluating financing, operational efficiencies and spending reductions, but stated those plans were not probable enough to alleviate the substantial doubt; additional financing was not assured.
COVID-19 effects on elective procedures, product development and operations remain uncertain. The company accrued $2.0 million for potential legal settlements as of June 30. After quarter-end, it paid $1.0 million to settle the Wainwright matter; a separate Cowen claim seeking a $1.35 million fee, plus fees and interest, remained unresolved in the filing. Management also disclosed ineffective internal control over financial reporting due to material weaknesses, including insufficient accounting resources and inadequate review of the weighted-average-share calculation. Remediation was underway.
Subsequent developments included the appointment of Paul F. Hickey as CEO effective August 15, 2022, succeeding Bart Bandy. The filing also describes plans to improve operating efficiency, shift marketing emphasis toward digital media, and continue developing products, but provides no quantified targets.
Most important facts for investors to verify
- Confirm the filing belongs to ReShape Lifesciences, not Vyome Holdings, before using it for company analysis.
- Assess cash runway against the disclosed $13.8 million first-half operating cash outflow and the going-concern warning; verify financing availability and subsequent cash developments.
- Track revenue recovery, marketing spending and margins, particularly whether management’s stated 2022 improvement expectation materialized.
- Review the potential dilution and terms of the June warrant exercise, repricing and newly issued warrants, alongside the increase in shares outstanding after quarter-end.
- Check the status and cash impact of the Cowen litigation claim, the Wainwright settlement payment, and remediation of the disclosed internal-control material weaknesses.